Law360 (June 7, 2018, 10:00 PM EDT) -- The Patent Trial and Appeal Board on Wednesday invalidated the entirety of a Kaken Pharmaceutical Co. patent used to create Valeant Pharmaceuticals International Inc.'s antifungal medication Jublia, finding that it had been anticipated by a series of prior art.
The board said neither of U.S. Patent Number 7,214,506's two claims could survive the challenge brought by generic drugmakers Acrux DDS Pty Ltd. and Argentum Pharmaceuticals LLC.
The final written decision notes that several pieces of prior art focus on using topical treatments on nails to treat toenail fungus, also called onychomycosis. Another piece of prior art focuses on the way a...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!